2024 年至 2031 年血型检测市场（按产品类型、检测类型、最终用户和地区划分）

血型鑑定市场评估，2024 年至 2031 年

自愿捐血量的增加促使对血型辨识和输血交叉配血程序的需求增加。因此，自愿捐血数量的增加推动了市场规模的激增，到 2024 年将超过 29.6 亿美元，到 2031 年将达到 61.6 亿美元的估值。

癌症、血液疾病和慢性贫血等疾病的发生率不断上升，推动了输血的需求，因此也推动了血型鑑定的需求。因此，由于需要输血的慢性病发生率不断上升，市场将从 2024 年到 2031 年的复合年增长率达到 9.60%。

血型鑑定市场定义/概论

血型鑑定是一项重要的医疗程序，透过识别红血球表面的某些抗原来确定一个人的血型。这个过程用于各种医疗程序，例如确保输血和器官移植的兼容性，以及管理妊娠以防止新生儿溶血性疾病（当母亲的免疫系统攻击胎儿的红血球时发生）。重要。

由于输血和器官移植的需求不断增加，对准确血型的需求也不断增加。根据世界卫生组织（WHO）的报告，自愿捐血人数大幅增加，2008年至2018年间捐血次数增加了1070万次，血型鑑定数量也相应增加。世界各地事故、创伤和伤害数量的增加进一步推动了这种需求的成长。研究表明，每 10 例创伤死亡病例中，就有 6 例是由于最初 3 小时内失血过多造成的，这凸显了及时输血（需要准确进行血型鑑定）的重要性。

基因检测和分子诊断的进步正在提高血型检测的准确性和速度，为更精准、个人化的医疗保健解决方案铺平了道路。随着医疗保健系统优先考虑患者安全和个人化治疗，对可靠血型的需求预计将增长，从而推动医疗保健应用的进一步扩展。

血型检测方法的技术进步将如何推动血型检测市场的成长？

血型技术的创新，例如分子分型和自动化系统，提高了血型测试的效率和准确性。根据《输血医学评论》杂誌 2020 年发表的一项研究，2015 年至 2019 年间，血库中自动血型分型系统的采用率增加了 35%。医疗保健提供者和患者对准确血型重要性的认识不断提高，推动了市场的成长。 2018 年，负责认证美国医疗机构的联合委员会报告称，实施包括严格的输血前检测在内的患者血液管理计划，使参与计划的医院的血液製品使用量平均减少了 12%。

外科手术数量的增加（其中许多需要输血）推动了对血型鑑定的需求。根据美国疾病管制与预防中心（CDC）的报告，2018年美国医院共进行了4,830万例外科和非外科手术，其中许多手术需要进行血型鑑定，并且有可能进行输血。人们对产前和新生儿护理的日益关注，包括母亲和胎儿的血型匹配，正在推动市场成长。根据国家生命统计报告，2019年美国将有约375万名新生儿，每个新生儿都可能需要对母亲和婴儿进行血型检测。

新兴国家缺乏基础设施和先进血型技术成本高昂将如何阻碍血型检测市场的成长？

特别是在新兴国家，缺乏血型检测基础设施是一个重大障碍。根据2019年世界卫生组织（WHO）的报告，只有62%的国家有国家血液政策，中低收入国家的比例最低，为48%。现代血型测定设备和试剂价格昂贵，限制了它们的应用，特别是在资源匮乏的环境中。 《输血医学》杂誌 2018 年发表的一项研究估计，在一个中型血库中实施全自动血型分型系统的成本将在 10 万至 50 万美元之间，这可能会限制该系统的广泛应用。

缺乏训练有素的人员来操作先进的血型系统，阻碍了市场的成长。根据美国临床病理学会2018年职缺调查显示，美国血库技术员/专家的空缺率为10.6%，显示该领域的技能型专业人员严重短缺。手动方法仍然被广泛使用，特别是在资源有限的环境中，但容易出现人为错误，从而限制信任和采用。 《输血》杂誌发表的 2020 年统合分析发现，手动血型分型的错误率为 0.05% 至 0.8%，取决于特定技术和环境。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况 市集亮点

第3章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章 血型检测市场（依产品类型划分）

• 消耗品
• 装置
• 服务

第 5 章血型检测市场（依检测类型划分）

• ABO
• 抗原
• 抗体
• 人类白血球抗原

第6章 血型分型市场（依方法划分）

基于分析
• PCR 方法
• 微阵列
• 大规模平行定序

第 7 章 血型分型市场（依最终用户划分）

• 医院
• 血库

第 8 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 9 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 10 章 竞争格局

• 大型公司
• 市占率分析

第 11 章 公司简介

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols
• S.A.
• Immucor, Inc.
• Ortho Clinical Diagnostics
• Quotient Limited
• BioMerieux SA
• DiaSorin S.p.A.
• Merck KGaA

第12章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 13 章附录

• 缩写列表
• 来源与参考文献

Blood Group Typing Market Valuation - 2024-2031

The increase in voluntary blood donations has led to a higher demand for blood group recognition and cross-matching procedures for transfusion. Thus, the increase in voluntary blood donations surged the growth of market size surpassing USD 2.96 Billion in 2024 to reach the valuation of USD 6.16 Billion by 2031.

The increasing incidence of diseases like cancer, blood disorders, and chronic anemia is driving the need for blood transfusions and, consequently, blood typing. Thus, the rising prevalence of chronic diseases requiring blood transfusions enables the market to grow at aCAGR of 9.60% from 2024 to 2031.

Blood Group Typing Market: Definition/ Overview

Blood group typing is a vital medical procedure that determines a person's blood type by identifying specific antigens on the surface of red blood cells. This process is crucial in various medical applications, such as ensuring compatibility for blood transfusions and organ transplants, as well as managing pregnancies, to prevent hemolytic disease of the newborn, which occurs when the mother's immune system attacks the fetus's red blood cells.

The demand for accurate blood group typing continues to grow, driven by the increasing need for blood transfusions and organ transplantations. The World Health Organization (WHO) reports a significant rise in voluntary blood donations, with an increase of 10.7 million donations between 2008 and 2018, indicating a corresponding rise in blood typing procedures. This rise in demand is further fueled by the growing number of accidents, trauma, and injury cases worldwide. Research indicates that 6 out of 10 trauma-related deaths result from excessive bleeding within the first three hours, underscoring the importance of timely blood transfusions, which require accurate blood group typing.

Advancements in genetic testing and molecular diagnostics are enhancing the accuracy and speed of blood typing procedures, paving the way for more precise and tailored healthcare solutions. As healthcare systems prioritize patient safety and personalized treatment, the demand for reliable blood group typing is expected to rise, further expanding its medical and healthcare applications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How the Technological Advancements in Blood Typing Methods Surge the Growth of Blood Group Typing Market?

Innovations in blood typing technologies, such as molecular typing and automated systems, are enhancing the efficiency and accuracy of blood group typing. A 2020 study published in the journal Transfusion Medicine Reviews found that the adoption of automated blood typing systems in blood banks increased by 35% between 2015 and 2019. Increased awareness among healthcare providers and patients about the critical nature of accurate blood typing is driving market growth. The Joint Commission, which accredits healthcare organizations in the U.S., reported in 2018 that the implementation of patient blood management programs, which include robust pre-transfusion testing, reduced blood product utilization by an average of 12% in participating hospitals.

The rising number of surgical procedures, many of which require blood transfusions, is boosting the demand for blood group typing. The Centers for Disease Control and Prevention (CDC) reported that in 2018, there were 48.3 million surgical and nonsurgical procedures performed in U.S. hospitals, with many requiring blood typing and potential transfusions. The growing focus on prenatal and neonatal care, including blood type compatibility testing between mother and fetus, is driving market growth. According to the National Vital Statistics Reports, there were approximately 3.75 million births in the United States in 2019, each potentially requiring blood typing for both mother and child.

How do the Lack Of Infrastructure in Emerging Countries and the High Cost Of Advanced Blood Typing Technologies Impede the Growth of the Blood Group Testing Market?

The lack of infrastructure for blood group typing, especially in emerging countries, is a significant restraint. According to a 2019 World Health Organization report, only 62% of countries had national blood policies, with lower-middle-income countries having the lowest rate at 48%. The expensive nature of modern blood typing equipment and reagents limits adoption, especially in resource-constrained settings. A 2018 study published in the journal Transfusion Medicine estimated that the cost of implementing a fully automated blood typing system in a medium-sized blood bank could range from $100,000 to $500,000, potentially limiting widespread adoption.

The lack of trained personnel to operate advanced blood typing systems hinders market growth. The American Society for Clinical Pathology's 2018 Vacancy Survey reported a vacancy rate of 10.6% for blood bank technologists/specialists in the United States, indicating a significant shortage of skilled professionals in the field. While manual methods are still widely used, especially in resource-limited settings, they are prone to human error, which can limit trust and adoption. A 2020 meta-analysis published in the journal Transfusion found that the error rate in manual blood typing ranged from 0.05% to 0.8%, depending on the specific technique and setting.

Category-Wise Acumens

How did the Increasing Chronic Disorders and Growing Number of Surgical Procedure Surge the Growth of the ABO Segment?

The ABO segment is dominant in the blood group testing market, driven by the rising prevalence of chronic diseases and the increasing number of surgical procedures requiring blood transfusions. Accurate ABO blood typing is crucial in ensuring compatibility between blood donors and recipients, significantly reducing the risk of adverse reactions during medical procedures. As a result, there has been a notable surge in demand for ABO blood typing tests, which is propelling the growth of this market segment.

Moreover, advancements in medical technology and diagnostic instruments have significantly enhanced the accuracy and efficiency of blood typing systems. The ability to swiftly and accurately determine blood types through automated methods has heightened the demand for ABO blood typing tests. Healthcare professionals prioritize patient safety and the reliability of medical procedures, making ABO testing an indispensable tool in modern healthcare. This growing emphasis on precision and efficiency ensures that the ABO segment will continue to dominate the blood group testing market in the years to come.

How the Extensive Use of Reagents & Kits in Blood Donation and Transfusion Procedure Surge the Growth of Reagents & Kits Segment?

The reagents & kits segment holds a dominant position in the blood group testing market, driven by their extensive use in blood donation and transfusion procedures. These products are essential for accurate blood typing, making them a critical component in ensuring compatibility between donors and recipients, particularly in life-saving situations such as surgeries, trauma care, and organ transplants. As the global demand for blood donations and transfusions continues to rise, the use of reagents & kits in healthcare facilities and blood banks has significantly increased, fueling the segment's growth.

The surge in voluntary blood donations and the expansion of healthcare infrastructure worldwide. With more individuals donating blood, the demand for reliable and efficient blood typing reagents has become paramount. Additionally, reagents are indispensable in determining blood types quickly and accurately, ensuring patient safety during transfusion procedures.

In addition, the segment is poised for continued growth as the adoption of advanced diagnostic technologies accelerates. As healthcare systems increasingly rely on automated and high-throughput instruments for blood typing, the need for specialized reagents & kits to complement these systems is expected to rise, ensuring the segment's strong presence in the market throughout the forecast period.

Country/Region-wise Acumens

How does the Significant Demand for Blood Transfusions Accelerate the Growth of the Blood Group Typing Market in North America?

North America substantially dominates the blood group testing market owing to the high demand for blood transfusions in North America, particularly in the United States. According to the American Red Cross, approximately 29,000 units of red blood cells are needed every day in the U.S. The organization also reports that nearly 16 million blood components are transfused each year in the United States.

The increased adoption of automated blood typing systems in North American healthcare facilities is driving market growth. A 2019 survey by the College of American Pathologists reported that 78% of participating laboratories in the U.S. and Canada were using fully or partially automated systems for ABO/Rh typing, up from 65% in 2014.

The favorable reimbursement policies for blood typing procedures and the rising number of regulatory approvals for advanced products are driving market growth in North America. The Centers for Medicare & Medicaid Services (CMS) reported that in 2020, the national average Medicare reimbursement for ABO and Rh blood typing (CPT code 86900) was $7.77, while for antibody screening (CPT code 86850) it was $17.28, providing financial incentives for healthcare providers to perform these tests. Additionally, the U.S. Food and Drug Administration (FDA) approved 12 new or updated blood typing-related products between 2018 and 2020, indicating a growing market for advanced blood typing technologies.

How the Rising Incidence of Chronic Diseases and Increasing Demand for Blood Transfusions Propel the Growth of Blood Group Testing Market in Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the blood group testing market driven by the prevalence of chronic diseases like cancer and kidney disorders is growing in Asia Pacific countries, leading to a higher demand for blood transfusions and typing. According to the World Health Organization (WHO), the number of new cancer cases in the Asia-Pacific region is expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This 30% increase will likely drive up the need for blood typing and transfusions.

Many Asia Pacific countries are investing heavily in healthcare infrastructure and increasing their healthcare spending, which supports the expansion of blood typing services. The Indian government's healthcare expenditure increased from 1.2% of GDP in 2013-14 to 1.8% in 2020-21, according to the Economic Survey 2020-21. This growth in healthcare spending is likely to boost investments in blood typing technologies and services.

There's an increasing awareness about the importance of blood donation in the region, supported by various government and non-government initiatives. In China, the number of voluntary blood donors increased from 12.32 million in 2011 to 15.48 million in 2019, according to data from the National Health Commission of China. This 25% increase in blood donors over eight years indicates a growing need for efficient blood typing services.

Competitive Landscape

The Blood Group Testing Market is a dynamic and competitive industry driven by factors such as increasing healthcare expenditure, growing awareness of blood group compatibility, and advancements in testing technologies. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers, blood banks, and individual consumers.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the blood group typing market include:

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche Ltd.
• Grifols, Immucor, Inc.
• Ortho Clinical Diagnostics
• Quotient Limited
• BioMerieux SA
• DiaSorin S.p.A.
• Merck KGaA.

Latest Developments:

• In June 2023, Quotient Limited announced the launch of its ALBA products in Sweden and the Netherlands. The items were also launched in France, Germany, Austria, Hungary, Italy, Greece, Poland, Romania, Luxembourg, and Slovakia.
• In June 2023, Quotient Limited announced an agreement with Transmedic Pte Ltd to distribute ALBA by Quotient and MosaiQ in five Southeast Asian countries: Indonesia, Singapore, Malaysia, Thailand, and Vietnam.
• In May 2023, Bio-Rad Laboratories, Inc. unveiled the IH-500TM NEXT System, a fully automated ID card system designed to address the changing demands and difficulties of the laboratory and healthcare environments.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Blood Group Typing Market, By Product

• Consumables
• Instruments
• Services

5. Blood Group Typing Market, By Test Type

• ABO
• Antigen
• Antibody
• HLA

6. Blood Group Typing Market, By Technique

• Assay-based
• PCR
• Microarray
• Massively Parallel Sequencing

7. Blood Group Typing Market, By End-User

• Hospital
• Blood Banks

8. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

9. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

10. Competitive Landscape

• Key Players
• Market Share Analysis

11. Company Profiles

• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols
• S.A.
• Immucor, Inc.
• Ortho Clinical Diagnostics
• Quotient Limited
• BioMerieux SA
• DiaSorin S.p.A.
• Merck KGaA

12. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

13. Appendix

• List of Abbreviations
• Sources and References